Loading candles…
Wanbury Ltd, incorporated in 1988 and headquartered in Navi Mumbai, India, operates as a vertically integrated pharmaceutical company. It engages in research, manufacturing, and exporting activities within the pharmaceutical industry, focusing on Active Pharmaceutical Ingredients (APIs) and pharmaceutical formulations. The company serves markets in India and over 50 countries worldwide. Wanbury holds a significant market share in products such as Metformin and Sertraline and has obtained regulatory approvals from agencies including the USFDA and EU-GMP. Its business model emphasizes being a preferred partner for global pharmaceutical companies. The company does not list any subsidiaries or key management details publicly.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | WANBURY : 29-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 14, 2026 has been re-scheduled. Further, the Company ha… | 29 May 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 14 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 4 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 15 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.